Literature DB >> 28069838

Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction: results of the ARREST study.

Alexander Romanov1, Martin Martinek2, Helmut Pürerfellner2, Shaojie Chen2, Mirko De Melis3, Igor Grazhdankin1, Dmitry Ponomarev1, Denis Losik1, Artem Strelnikov1, Vitaliy Shabanov1, Alexander Karaskov1, Evgeny Pokushalov1.   

Abstract

Aims: Cardiac arrhythmias following acute myocardial infarction (AMI) can be associated with major adverse cardiovascular events. Data on the "real incidence" of post-MI arrhythmias are limited. We aimed to determine the rate and burden of cardiac arrhythmias by the use of insertable cardiac monitors (ICM) in patients with preserved left ventricular ejection fraction (LVEF) after AMI. Methods and results: In this prospective observational study, patients with LVEF ≥40% who underwent PCI within 7 days following AMI were enrolled to receive an ICM. Primary outcome was the incidence of new-onset atrial fibrillation (AF) measured by the ICM during a follow-up of 2 years; results: Of 165 consecutive patients with AMI, 50 (30.3%) eligible patients were recruited (mean age 57.8 ± 8.3, 88% male). During follow-up, AF was the most frequently detected arrhythmia. Twenty-nine (58%, 95% CI: 42-70%) patients developed new-onset AF, with a cumulative rate of all detected arrhythmias of 65%. Median time to the first detected AF episode was 4.8 months and the peak cumulative AF burden was detected between 3 and 6 months. Twenty-seven (93%) out of 29 patients with AF were asymptomatic. Cox regression analysis found that baseline troponin level (hazard ratio [HR] for 1 ng/mL increment: 1.03, 95% CI: 1.01-1.06, P = 0.01) and CHA2DS2-VASc score of 4 (HR: 11.42, 95% CI: 1.01-129.06, P = 0.04) were independent risk factors of new-onset AF post-AMI.
Conclusion: AF is a frequent but largely underestimated cardiac arrhythmia after AMI. More rigorous monitoring strategies resulting in crucial medical interventions (e.g. implementation of oral anti-coagulation) are needed. Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT02492243. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Cardiac rhythm; Continuous monitoring; Implantable rhythm monitor; Myocardial infarction

Mesh:

Year:  2018        PMID: 28069838     DOI: 10.1093/europace/euw344

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  8 in total

1.  California study of Ablation (CAABL):early utilization after index hospitalization for non-valvular atrial fibrillation.

Authors:  Uma Srivatsa; Beate Danielsen; Ezra Amsterdam; Yingbo Yang; Dali Fan; Nayereh Pezeshkian; Richard H White
Journal:  J Atr Fibrillation       Date:  2017-06-30

2.  Predictions and Outcomes of Atrial Fibrillation in the Patients with Acute Myocardial Infarction.

Authors:  Mihailo Vukmirović; Aneta Bošković; Irena Tomašević Vukmirović; Radoje Vujadinovic; Nikola Fatić; Zoran Bukumirić; Filip Vukmirović
Journal:  Open Med (Wars)       Date:  2017-05-02

3.  Effects of atrial fibrillation on complications and prognosis of patients receiving emergency PCI after acute myocardial infarction.

Authors:  Yingchun Zhang; Lingzhi Zhang; Hongzhi Zheng; Hongfen Chen
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

4.  Clinical Management of Patients with First-Episode Atrial Fibrillation Detected in the Acute Phase of Myocardial Infarction.

Authors:  Mauricio Scanavacca; Tan Chen Wu
Journal:  Arq Bras Cardiol       Date:  2019-11       Impact factor: 2.000

Review 5.  Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.

Authors:  Emanuele Bertaglia; Benjamin Blank; Carina Blomström-Lundqvist; Axel Brandes; Nuno Cabanelas; G-Andrei Dan; Wolfgang Dichtl; Andreas Goette; Joris R de Groot; Andrzej Lubinski; Eloi Marijon; Béla Merkely; Lluis Mont; Christopher Piorkowski; Andrea Sarkozy; Neil Sulke; Panos Vardas; Vasil Velchev; Dan Wichterle; Paulus Kirchhof
Journal:  Europace       Date:  2019-10-01       Impact factor: 5.214

6.  CTRP9 Ameliorates Atrial Inflammation, Fibrosis, and Vulnerability to Atrial Fibrillation in Post-Myocardial Infarction Rats.

Authors:  Mingxin Liu; Wei Li; Huibo Wang; Lin Yin; Bingjie Ye; Yanhong Tang; Congxin Huang
Journal:  J Am Heart Assoc       Date:  2019-10-18       Impact factor: 5.501

7.  Coronary Artery Disease and Atrial Fibrillation: A Bidirectional Mendelian Randomization Study.

Authors:  Tao Yan; Shijie Zhu; Changming Xie; Miao Zhu; Fan Weng; Chunsheng Wang; Changfa Guo
Journal:  J Cardiovasc Dev Dis       Date:  2022-02-27

Review 8.  Use of Anticoagulant Therapy in Patients with Acute Myocardial Infarction and Atrial Fibrillation.

Authors:  Ratko Lasica; Lazar Djukanovic; Dejana Popovic; Lidija Savic; Igor Mrdovic; Nebojsa Radovanovic; Mina Radosavljevic Radovanovic; Marija Polovina; Radan Stojanovic; Dragan Matic; Ana Uscumlic; Milika Asanin
Journal:  Medicina (Kaunas)       Date:  2022-02-23       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.